Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 14,130 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Encephalitis, Japanese Encephalitis
Interventions: ChimeriVax-JE, Japanese Encephalitis vaccine, 0.9% Saline; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 2,004 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 16
States / cities: Burbank, California • Costa Mesa, California • Davis, California + 13 more

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly, Placebo; Drug
Lead sponsor: Immunovant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 21
States / cities: Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 17 more

Conditions: Hay Fever, Seasonal Allergic Rhinitis
Interventions: Ciclesonide nasal spray; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 71
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Costa Mesa, California + 65 more

Conditions: Vomiting
Interventions: DDP225; Drug
Lead sponsor: Dynogen Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 6
States / cities: Mobile, Alabama • Scottsdale, Arizona • Kansas City, Kansas + 3 more

Conditions: ADHD
Interventions: SPD489, Placebo; Drug · Other
Lead sponsor: Shire; Industry
Eligibility: 13 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 6
States / cities: Little Rock, Arkansas • Bradenton, Florida • Overland Park, Kansas + 3 more

Conditions: Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions: Canagliflozin, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 25 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 26
States / cities: Concord, California • Fountain Valley, California • San Diego, California + 23 more

Conditions: Cystic Fibrosis
Interventions: tgAAVCF; Genetic
Lead sponsor: Targeted Genetics Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 11
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 7 more

Conditions: Primary Immunodeficiency, Agammaglobulinemia, Hypogammaglobulinemia, Antibody Deficiency
Interventions: Kedrion IVIG 10%; Biological
Lead sponsor: Kedrion S.p.A.; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 12
States / cities: Little Rock, Arkansas • North Palm Beach, Florida • Atlanta, Georgia + 8 more

Conditions: Contraception
Interventions: MR-100A-01; Drug
Lead sponsor: Mylan Technologies Inc.; Industry
Eligibility: 16 Years and older · Female only
Enrollment: 1,320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 96
States / cities: Mobile, Alabama • Mesa, Arizona • Phoenix, Arizona + 72 more

Conditions: Bladder, Neurogenic
Interventions: tamsulosin hydrochloride, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 7
States / cities: Los Angeles, California • Tampa, Florida • St Louis, Missouri + 4 more

Conditions: Coronary Artery Bypass Surgery, Cognitive Impairment
Interventions: Angiotensin-(1-7), Placebo for Angiotensin-(1-7); Drug
Lead sponsor: University of Arizona; Other
Eligibility: 60 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 5
States / cities: Phoenix, Arizona • Tucson, Arizona • Bethesda, Maryland + 1 more

Conditions: Type 2 Diabetes Mellitus
Interventions: placebo, GSK376501; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Prurigo Nodularis
Interventions: Nemolizumab, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 22
States / cities: Fountain Valley, California • San Diego, California • Washington D.C., District of Columbia + 19 more

Conditions: Ulcerative Colitis
Interventions: ABX464 100 mg, ABX464 50 mg, ABX464 25 mg, Placebo; Drug
Lead sponsor: Abivax S.A.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: San Diego, California • Decatur, Georgia • Austin, Texas + 1 more

Conditions: Non-small Cell Lung Cancer
Interventions: HS110 vaccine, Placebo; Biological
Lead sponsor: Heat Biologics; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Rheumatoid Arthritis
Interventions: LX3305, LX3305 Placebo, Methotrexate; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypertension
Interventions: Darusentan, Guanfacine, Darusentan Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 849 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 87
States / cities: Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 70 more

Conditions: Wounds
Interventions: GLYC-101 Gel (0.1%), GLYC-101 Gel (1.0%), GLYC-101 Placebo; Drug
Lead sponsor: TR Therapeutics; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Pridopidine, Placebo; Drug
Lead sponsor: Prilenia; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 18
States / cities: Phoenix, Arizona • San Francisco, California • Aurora, Colorado + 14 more

Conditions: Opioid Use Disorder
Interventions: ASP8082, morphine, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Schizophrenia
Interventions: RBP-7000, Placebo, Risperidone; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 32
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Cerritos, California + 25 more

Conditions: Asthma
Interventions: GSK3511294, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 41
States / cities: Alabaster, Alabama • Mobile, Alabama • Phoenix, Arizona + 34 more

Conditions: Psoriasis
Interventions: Vehicle, M518101; Drug
Lead sponsor: Maruho North America Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 34
States / cities: Mesa, Arizona • Encino, California • San Diego, California + 29 more

Conditions: Ulcerative Colitis
Interventions: TLL018, Placebo; Drug · Other
Lead sponsor: TLL Pharmaceutical, LLC; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.

To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)

12 Weeks Treatment With DDP225 or Placebo in Patients With Chronic Functional Vomiting

Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

Safety and Efficacy of Recombinant Adeno-Associated Virus Containing the CFTR Gene in the Treatment of Cystic Fibrosis

Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)

Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles

Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder

Evaluation of the Safety and Efficacy of Ang-(1-7) to Enhance Cognitive Function in Participants Undergoing CABG

A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects

A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis

Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis

DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants

Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients

A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis

Safety and Efficacy Study of TLL018 in the Treatment of Ulcerative Colitis